For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Aligos Therapeutics, Inc.

USPTO Granted Patents = 34

EPO Patents = 1

Trademarks = 1

Forward Citations = 22

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

Leonid Beigelman (19 out of 224 patents)

Pierre Jean-Marie Bernard Raboisson (17 out of 178 patents)

Koen Vandyck (11 out of 44 patents)

4. David Craig McGowan (10 out of 61 patents)

5. Jerome Deval (10 out of 28 patents)

6. Sandrine Vendeville (10 out of 11 patents)

7. Antitsa Dimitrova Stoycheva (9 out of 19 patents)

8. Yannick Debing (6 out of 6 patents)

9. David Bernard Smith (5 out of 88 patents)

10. Vivek Kumar Rajwanshi (5 out of 18 patents)

11. Jin Hong (5 out of 10 patents)

12. Rajendra K Pandey (5 out of 7 patents)

13. Pierre Jean-Marie Bernard Raboisson (5 out of 6 patents)

14. Tongfei Wu (4 out of 27 patents)

15. Dorothée Alice Marie-Eve Bardiot (4 out of 24 patents)

34 patents: Sort by Forward Citations

1. 12454691 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2025-10-28),

2. 12428427 - Methods and compositions for targeting PD-L1 (2025-09-30),

3. 12384779 - Bicyclic compounds (2025-08-12),

4. 12252481 - Anti-viral compounds (2025-03-18),

5. 12180192 - Modulators of THR-β and methods of use thereof (2024-12-31),

6. 12129469 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2024-10-29),

7. 12065428 - Anti-viral compounds (2024-08-20),

8. 12018015 - Methods and compositions for targeting PD-L1 (2024-06-25),

9. 11957683 - Bicyclic compounds (2024-04-16),

10. 11952374 - Bicyclic compounds (2024-04-09),

11. 11952365 - Anti-viral compounds (2024-04-09),

12. 11939581 - Methods and compositions for targeting PD-L1 (2024-03-26),

13. 11858913 - Bicyclic pyridazinones and methods of use thereof (2024-01-02),

14. 11851422 - Anti-viral compounds (2023-12-26),

15. 11845752 - Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B (2023-12-19),

Aligos Therapeutics, Inc. is a biotechnology company focused on the development of therapeutics for viral infections and liver diseases. Leveraging their expertise in virology, drug discovery, and the liver, they aim to discover and develop targeted antiviral therapies to address significant unmet medical needs. With a focus on chronic hepatitis B (HBV) and nonalcoholic steatohepatitis (NASH), Aligos Therapeutics aims to improve patient outcomes and provide effective treatments for these diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

34 Patents

#42 in South San Francisco, CA

#2,306 in California

#9,678 in US

#19,057 in the World

South San Francisco, CA, United States of America

Aligos Therapeutics, Inc.

Forward Citations = 22

31 inventors:

Leonid Beigelman (19 out of 224 patents)

Pierre Jean-Marie Bernard Raboisson (17 out of 178 patents)

Koen Vandyck (11 out of 44 patents)

4. David Craig McGowan (10 out of 61 patents)

5. Jerome Deval (10 out of 28 patents)

Please report any incorrect information to support@idiyas.com

Loading…